ALIPAY+
15.7.2024 09:33:27 CEST | Business Wire | Press release
In a fiercely contested UEFA EURO 2024™, Dani Olmo (Spain), Harry Kane (England), Cody Gakpo (Netherlands), Georges Mikautadze (Georgia), Ivan Schranz (Slovakia), and Jamal Musiala (Germany) emerged as joint winners of the Alipay+ Top Scorer award. Each player scored three goals during the tournament, showcasing exceptional performances throughout and contributing to a memorable event that concluded with a thrilling final at Berlin's Olympiastadion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240714542692/en/
Eric Jing, Chairman and CEO of Ant Group, presents the Alipay+ Top Scorer award to the onsite winning football player Dani Olmo of Spain at UEFA EURO 2024™ (Photo: Business Wire)
“Our warmest congratulations to the six exceptional football players for their stellar performances and for winning the Alipay+ Top Scorer award,” said Eric Jing, Chairman and CEO of Ant Group, while presenting the award at the Berlin Olympiastadion. “Just as these athletes push the boundaries of excellence with strength, ingenuity and teamwork, Alipay+ advances global commerce through digital innovation, empowering people and businesses worldwide.”
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International, is the Official Partner of UEFA EURO 2024™. The Alipay+ Top Scorer trophy, sculpted in the shape of the Chinese character “支” (pronounced zhi, meaning payment as well as support), reflects Alipay+’s dedication to supporting consumers to enjoy seamless cross-border payment and access personalised deals when using their preferred payment methods while traveling abroad.
The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that unit people across the world with passion, ambition, and solidarity. The base of the trophy resembles the ocean, consisting of 24 undulating pieces each inscribed with the names of the participating countries, while the design symbolizes the 24 teams braving the waves at the competition. The ocean also connects continents, which represents how football connects communities across the world similar to Alipay+ connecting global commerce.
Alipay+ has now enabled over 400,000 merchants in Europe, with over 120,000 in the DACH region alone. Among the 15 Alipay+ mobile partners in Germany are Alipay (Chinese mainland), AlipayHK (Hong Kong SAR, China), MPay (Macao SAR, China), Touch ’n Go eWallet and MyPB by Public Bank Berhad (Malaysia), Hipay (Mongolia), GCash (The Philippines), OCBC Digital and Changi Pay (Singapore), TrueMoney (Thailand), Tinaba (Italy), Bluecode (Germany and Austria) and Kakao Pay, Naver Pay and Toss Pay (South Korea).
“With Alipay+ and our global partnerships, global fans and visitors explore Germany, Europe and the bigger world seamlessly using their preferred payment methods. Digital commerce connects communities worldwide just like football,” said Jing. “Looking ahead, we are committed to advancing digital technologies for everyone, supporting a robust, inclusive, and sustainable global digital economy.”
About Alipay+
Alipay+ is a suite of cross-border mobile payment and digitalization technology solutions that help connect global merchants to consumers. Consumers enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. Small and medium-sized businesses may use Alipay+ digital tools to enhance efficiency and achieve omni-channel growth.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240714542692/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom